The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Tissue Regenix Group PLC (LON:TRX), a company listed on the FTSE AIM 100 Index, is engaged in the regenerative medical devices sector. This area of medical technology specializes in advanced human ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

GSK plc announced that the European Medicines Agency has accepted for review the marketing authorisation application (MAA) for the use of linerixibat, an investigational targeted inhibitor of the ...

GSK plc (LSE/NYSE:GSK) announced Monday that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for linerixibat, an investigational treatment for ...

The MAA for linerixibat was based on positive data from the phase III GLISTEN study. The study met both the primary and key secondary endpoints, wherein treatment with linerixibat led to a rapid, ...

Despite the rise in catastrophic events, the property and casualty (P&C) insurance industry is poised for continued growth, fueled by a shift toward personalized offerings and enhanced customer ...